Related Experiment Video

Updated: Oct 16, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K

The implications of ABCC3 in cancer drug resistance: can we use it as a therapeutic target?

Adriana Ramírez-Cosmes1, Edilburga Reyes-Jiménez1, Cecilia Zertuche-Martínez1

  • 1Laboratorio Fibrosis y Cáncer, Facultad de Medicina y Cirugía, Universidad Autónoma "Benito Juárez" de Oaxaca Oaxaca, Oax, México.

American Journal of Cancer Research
|October 18, 2021
PubMed

Insights

Drug resistance in cancer is a major challenge, often caused by efflux pumps like ABCC3. Targeting ABCC3 offers a promising strategy to overcome multidrug resistance and improve chemotherapy effectiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Drug resistance significantly contributes to chemotherapy failure.
  • Overexpression of efflux pumps, such as ABCC3, reduces intracellular drug concentration and efficacy.
  • ABCC3 is implicated in multidrug resistance and is highly expressed in various cancers, correlating with poor prognosis.

Purpose of the Study:

  • To review the molecular mechanisms of cancer drug resistance.
  • To discuss the structure, function, and role of ABCC3 in mediating drug resistance.
  • To examine the expression patterns of ABCC3 across different cancer types.

Main Methods:

  • Literature review of molecular mechanisms in cancer drug resistance.
  • Analysis of existing research on ABCC3 structure and function.
  • Compilation of data on ABCC3 expression in various cancers.

Main Results:

  • ABCC3 overexpression is a key factor in multidrug resistance.
  • High ABCC3 expression is linked to poor treatment outcomes in multiple cancer types.
  • ABCC3's role in drug efflux is a significant challenge in cancer therapy.

Conclusions:

  • ABCC3 is a critical mediator of cancer multidrug resistance.
  • Targeting ABCC3 presents a potential therapeutic strategy for enhancing cancer treatment.
  • Further translational research is needed to develop effective ABCC3-targeted therapies.
Keywords:
ABCC3Cancerdrug resistancetherapeutic targettransporters

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
ABC Transporters: Exporter01:31

ABC Transporters: Exporter

ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
5.3K
ABC Transporters: Importer01:27

ABC Transporters: Importer

ATP-binding cassette or ABC transporters are a class of ATP-driven pumps that hydrolyze ATP to move solutes across the membrane. They can be grouped into importers and exporters. While exporters are present in all domains of life, importers exist only in bacteria and some plants.
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
3.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K